Company news
Sab Biotherapeutics, Inc. (NASDAQ:SABS) news
Sab Biotherapeutics, Inc. news releases on 6ix. Latest, Oct 25, 2021: SAB Biotherapeutics Debuts as Publicly Traded Next-Generation Immunotherapy Company
Press releases — page 3
SAB Biotherapeutics Debuts as Publicly Traded Next-Generation Immunotherapy Company
October 24, 2021
SAB Biotherapeutics to Host Virtual R&D Day on October 13, 2021
October 5, 2021
SAB Biotherapeutics Announces First Patient Dosed in Phase 3 NIH ACTIV-2 Trial Evaluating SAB-185 for Treatment of COVID-19
October 3, 2021
SAB Biotherapeutics Appoints Russell Beyer Chief Financial Officer
September 27, 2021
SAB Biotherapeutics Announces SAB-185 Receives Positive DSMB Review and Advances to Phase 3 in NIH-Sponsored ACTIV-2 Trial for Treatment of COVID-19
September 23, 2021
SAB Biotherapeutics Awarded Additional $60.5M from BARDA and U.S. Department of Defense for Rapid Response Capability and Advancing SAB-185 for Treatment of COVID-19
September 21, 2021
SAB Biotherapeutics Announces Completion of Enrollment in Phase 2a Challenge Trial of SAB-176 for the Treatment of Seasonal Influenza
September 14, 2021
SAB Biotherapeutics Announces Nonclinical Data Demonstrating SAB-185 Potently Neutralizes Delta and Lambda SARS-CoV-2 Variants
August 10, 2021
SAB Biotherapeutics Announces Publication of Preclinical Data Demonstrating SAB-185 Effectively Neutralizes SARS-CoV-2 Variants
July 7, 2021
SAB Biotherapeutics to List on Nasdaq through Merger with Big Cypress Acquisition Corp., Advancing Unique Human Antibody Platform with Demonstrated Utility in Immunotherapy and Rapid Response to Emerging Diseases
June 21, 2021